TargED Biopharmaceuticals key facts
as of Oct 2026- Developer of biopharmaceutical drugs intended to serve doctors and healthcare professionals to improve the treatment of thrombosis.
- TargED Biopharmaceuticals is valued at approximately $50.0M as of Oct 2026 (last reported valuation).
- It has raised $72.2M; the latest was Later Stage VC ($70.3M) in Dec 2025.
- Notable investors include European Innovation Council, Andera Partners, Utrecht Holdings, Rotrip Europe, BioGeneration Ventures — 17 tracked in total.
- Status: Privately Held (backing).
TargED Biopharmaceuticals's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch TargED Biopharmaceuticals: the Monday email on marks, rounds and moves
TargED Biopharmaceuticals funding rounds
No funding rounds for TargED Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs TargED Biopharmaceuticals
17+TargED Biopharmaceuticals valuation
TargED Biopharmaceuticals's last reported valuation was $50 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
TargED Biopharmaceuticals investors
17 investors are on record for TargED Biopharmaceuticals, including European Innovation Council, Andera Partners, Utrecht Holdings and Rotrip Europe.
About TargED Biopharmaceuticals
Developer of biopharmaceutical drugs intended to serve doctors and healthcare professionals to improve the treatment of thrombosis. The company offers small antibody-based therapies that deliver enzymes directly to disease sites, enabling clients to accelerate treatment and enhance patient outcomes.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2018
- Employees
- 33
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.